Two out of the three core focus indications are funded to completion.
There are challenges but there are also options for funding, potential positive data and a significantly improved SP, (which also brings benefits for funding). The challenges around funding is noted but talking about insolvent trading is a misleading distraction.
- Forums
- ASX - By Stock
- Ann: EVT801 preclinical data published
Two out of the three core focus indications are funded to...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online